Is a
Patent attributes
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
Date of Patent
June 21, 2016
Patent Application Number
14923879
Date Filed
October 27, 2015
Patent Citations Received
Patent Primary Examiner
Patent abstract
The disclosure provides antibodies that are useful for, among other things, inhibiting terminal complement (e.g., the assembly and/or activity of the C5b-9 TCC) and C5a anaphylatoxin-mediated inflammation and, thus, treating complement-associated disorders. The antibodies have a number of improved properties relative to eculizumab, including, e.g., increased serum half-life in a human.
Timeline
No Timeline data yet.
Further Resources
No Further Resources data yet.
